Drug Profile
Anti-CD19 anti-BCMA bispecific chimeric antigen receptor T cell therapy - Hrain Biotechnology
Alternative Names: Anti-CD19/BCMA bispecific CAR T cell therapy; Anti-CD19/BCMA CAR-T cellsLatest Information Update: 28 Aug 2022
Price :
$50
*
At a glance
- Originator HRAIN Biotechnology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Multiple myeloma; POEMS syndrome
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in China (IV, Infusion)
- 28 Apr 2022 No recent reports of development identified for phase-I development in POEMS-syndrome(Second-line therapy or greater) in China (Parenteral)
- 01 Jul 2019 HRAIN Biotechnology plans a phase I trial in Multiple myeloma (Second-line therapy or greater) in China (NCT04003168)